Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bosutinib - Pfizer

Next Previous
Drug Profile

Bosutinib - Pfizer

Alternative Names: Bosulif; Bosutinib monohydrate - Pfizer; PF-05208763; PF-5208763; SKI-606

Latest Information Update: 17 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Aniline compounds; Antineoplastics; Chlorine compounds; Nitriles; Piperazines; Quinolines; Small molecules; Urologics
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Src-family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Glioblastoma
  • Phase I/II Amyotrophic lateral sclerosis; Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Autosomal dominant polycystic kidney disease; Breast cancer; Solid tumours

Most Recent Events

  • 31 Dec 2024 St. Olavs Hospital in collaboration with Pfizer completes the phase II BosuPeg trial in Chronic myeloid leukaemia (Monotherapy, First-line therapy) in Sweden, Norway, Finland, Denmark (PO) (NCT03831776) (EudraCT2018-001044-54)
  • 31 Dec 2024 St. Olavs Hospital in collaboration with Pfizer completes the phase II BosuPeg trial in Chronic myeloid leukaemia (Combination therapy, First-line therapy) in Sweden, Norway, Finland, Denmark (PO) (NCT03831776) (EudraCT2018-001044-54)
  • 07 Dec 2024 Efficacy and adverse events data from a subcohort of phase II Bodo trial in Chronic myeloid leukaemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top